<DOC>
	<DOCNO>NCT01468181</DOCNO>
	<brief_summary>This 52-week , multicenter , non-randomized , open-label , Phase 3 long-term safety study participant type 2 diabetes mellitus inadequate glycemic control monotherapy oral antihyperglycemic medication ( OAM ) .</brief_summary>
	<brief_title>A Study LY2189265 Japanese Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Participants diagnosis type 2 diabetes mellitus screen Participants take SU ( Glibenclamide , Gliclazide , Glimepiride ) , BG , TZD , aGI glinides monotherapy least 3 month screen stable dose least 8 week screen Participants must qualify HbA1c value 7.0 % 11.0 % screen Participants body mass index ( BMI ) 18.5 35.0 kilogram per meter square ( kg/m^2 ) Participants diagnosis type 1 diabetes Participants previously treat glucagonlike peptide1 ( GLP1 ) analog within 3 month screen Participants currently take insulin previous insulin treatment within 3 month screen Participants obvious clinical sign symptom pancreatitis , history chronic pancreatitis , acute pancreatitis screening , determine investigator . Participants serum amylase concentration ≥3 time upper limit reference range and/or serum lipase concentration ≥2 time upper limit reference range , determined central laboratory screen Participants self family history medullary Ccell hyperplasia , focal hyperplasia , medullary thyroid carcinoma ( MTC )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Oral antihyperglycemic medication</keyword>
	<keyword>Long-Term Safety</keyword>
	<keyword>GLP 1</keyword>
	<keyword>Glucagon like peptide 1</keyword>
</DOC>